周海兵（Zhou Haibing）博士

9778818威尼斯珞珈特聘教授、博士生导师。教育部新世纪优秀人才、湖北省首届医学领军人才、病毒学国家重点实验室学术带头人、湖北省有机氟类药物工程技术研究中心主任 

通讯地址：

9778818威尼斯，湖北省武汉市武昌区东湖路185号。邮编：430071。

E-mail: zhouhb@whu.edu.cn  

教育与研究经历:

2007/12-至今：9778818威尼斯，教授、博导

2003/12-2007/11：美国伊利诺伊大学香槟分校，博士后

2001/9-2003/12：加拿大渥太华大学，博士后

1997/09-2000/07：四川大学 有机化学 博士

1994/09-1997/07：四川大学 有机化学 硕士

1990/09-1994/07：延安大学 化学 学士  

业绩概要:

主要从事抗肿瘤、抗病毒药物的设计、合成与开发。长期从事雌激素受体（ER）的细胞特异性分子调控机制和结构新颖的SERMs、SERDs及PROTACs类药物的设计、合成和活性研究。已发表SCI论文90余篇，多篇论文发表在Nature Chemical Biology, Molecular Systems Biology, Chemistry Biology, J. Med. Chem.等国际著名期刊上。其中以第一作者或通讯作者在药物化学顶尖期刊J. Med. Chem.上发表论文11篇。获批中国专利27项。主持国家自然科学基金重大研究计划培育项目及面上项目、教育部新世纪优秀人才支持计划项目、教育部科学技术研究重大项目、教育部博士点博导类基金等项目20余项。 

荣誉及奖励:

2021年湖北省科学技术进步奖二等奖（第三完成人）

2020-2021学年9778818威尼斯本科优秀教学业绩奖

2016年湖北省自然科学奖三等奖（第一完成人）

2013年湖北省首届医学领军人才

2012年9778818威尼斯珞珈特聘教授

2010年药明康德生命化学研究奖

2009年教育部新世纪优秀人才

研究领域:

• 药物化学，有机化学 

研究兴趣与方向：

• 基于靶点（雌激素受体、病毒复制关键因子等）的抗肿瘤、抗病毒药物研究

• 新型选择性雌激素受体调节剂 (SERMs)、选择性雌激素受体下调剂 (SERDs)以及PROTACs的设计、合成与活性研究；用于乳腺癌早期诊断的新型分子探针及显影剂的设计、合成

• 多样性导向合成（Diversity-oriented synthesis）及合理药物设计在化学生物学及药物发现中的应用 

近5年承担课题：

• 主持国家自然科学基金面上项目(No. 82073690), 2021.01-2024.12

• 主持国家自然科学基金面上项目(No. 81773557), 2018.01-2021.12

• 主持国家自然科学基金面上项目(No. 81573279), 2016.01-2019.12

• 主持湖北省技术创新专项重大项目(No. 2016ACA126), 2016.07-2018.06 

指导国家级大学生创新创业训练项目：

2009年度：新型选择性雌激素受体调节剂（SERMS）的设计合成及生物活性研究（许超凡，肖玉兰，任文明，张凤，王凯）

2010年度：具有特殊结构的新型雌激素受体配体的设计合成及生物活性研究(唐娟，左自青，熊啸林，张鑫龙，云泰康祥)

2011年度：新型选择性雌激素受体下调剂（SERDs）的设计合成及生物活性研究（王志强，李金富，李贺，吴凤意，郭超）

2012年度：新型兼具抗乳腺癌活性和抗炎活性雌激素受体调节剂的设计、合成及其生物活性研究（郭芳，李沂霖，李守吉，林祖明）

2013年度：基于双靶点的新型抗肿瘤药物的设计、合成及生物活性研究（李一婧，陈玉玲，孔德瑛，宁文涛）

2014年度：新型吲哚类衍生物的不对称合成及其抗HIV生物活性研究（樊甜甜，胡雅丽，戴云飞，李彬，瞿向利）（获第七届全国大学生药苑论坛优秀项目三等奖）

2016年度：新型含硒类选择性雌激素受体调节剂（SERMs）的设计、合成及生物活性研究（梁家恩，张斌，倪智豪）

2017年度：嵌入抗炎优势基团的选择性雌激素受体调节剂的设计、合成和抗肿瘤活性研究（刘凡玉，杜川黔，刘豫，何雪）

2018年度：新型兼具抗炎和抗流感病毒H5N1活性双功能小分子抑制剂研究（杨通莹，胡陈娴，王鹏宇，董彬，陈文博）

2019年度，含碳硼烷结构的新型选择性雌激素受体调节剂的设计、合成和活性研究（余绿珊，李锐涵，周乃鹏，刘蒙昊）。

2021年度，含有疏水性氨基酸标签的新型雌激素受体降解剂（SERDs）的设计、合成及生物活性研究（乃皮赛·麦麦提阿卜杜拉、易萍、伊丽米努尔·艾散）

指导省级大学生创新创业训练项目：

2021年度，新型抗耐药性广谱抗病毒PROTAC分子的设计、合成和活性研究 (杨茂泽，李宝萍，金伊楠，吴媛媛)

教学情况：

• 本科生：药物化学

• 研究生：高等有机化学

• 博士生：药物化学进展、专业英语 

教改课题：

• 主持中国学位与研究生教育学会教育研究课题，“多模态学科交叉人才培养体系与复合型创新医学人才培养探索”，2019年5月至2021年4月

• 主持2011年9778818威尼斯研究生全英文课程——“高等有机化学”建设项目 

学术兼职:

• 全国药学专业学位研究生教育指导委员会委员

• 中国药学会药物化学专业委员会委员

• 全国卫生产业企业管理协会精准医疗分会理事

• 湖北省药学会常务理事、药物化学专业委员会主任委员

• 《Pharmaceutics》、《Frontiers in Drug Discovery》、《中国药学》(英文版)、《药学学报》、《中国药物化学杂志》、《现代药物与临床》、《高等药学教育研究》等杂志编委
  

代表性论文：

1. Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: An Orally Bioavailable, Potential and Multi-acting Class of Estrogen Receptor Modulators against Endocrine-Resistant Breast Cancer. Xiangping Deng, Baohua Xie, Qiuzi Li, Yuan Xiao, Zhiye Hu, Xiaofei Deng, Pingping Fang,* Chune Dong,* Hai-Bing Zhou,* and Jian Huang,* J. Med. Chem., 2022, 65 (11), 7993–8010. (IF: 8.039)

2. Discovery of Aryl Benzoyl Hydrazide Derivatives as Novel Potent Broad-Spectrum Inhibitors of Influenza A Virus RNA Dependent RNA Polymerase (RdRp). Xinjin Liu,† Jinsen Liang,† Yongshi Yu,b,† Xin Han, Lei Yu, Feifei Chen, Zhichao Xu, Qi Chen, Mengyu Jin, Chune Dong, Hai-Bing Zhou*, Ke Lan*, and Shuwen Wu*. J. Med. Chem., 2022, 65 (5), 3814–3832. (IF: 8.039)

3. ERβ-Targeted Near-Infrared Inherently Fluorescent Probe: A Potent Tool for ERβ Research. Qiuyu Meng#, Baohua Xie#, Huiguang Yu, Kang Shen, Xiangping Deng, Hai-Bing Zhou,* Chune Dong*. ACS Sensors 2022, 7 (1), 109–115. (IF: 9.618)

4. Estrogen receptor β-targeted hypoxia-responsive near-infrared fluorescence probes for prostate cancer study. Baohua Xie†, Qiuyu Meng†, Huiguang Yu, Kang Shen, Yan Cheng, Chune Dong*, Hai-Bing Zhou*. Eur. J. Med. Chem., 2022, 238, 114506. (IF: 7.088)

5. Discovery of Oseltamivir-Based Novel PROTACs as Degraders Targeting Neuraminidase to Combat H1N1 Influenza Virus. Zhichao Xu, Xinjin Liu, Xiaoyu Ma, Wenting Zou, Qi Chen, Feifei Chen, Xiaofei Deng, Jinsen Liang, Chune Dong, Ke Lan*, Shuwen Wu* and Hai-Bing Zhou*. Cell Insight 2022, 1 (3), 100030.

6. Discovery of Aminothiazole Derivatives as Novel Human Enterovirus A71 Capsid Protein Inhibitors. Zhichao Xu,# Qi Tangb,# Ting Xu, Yang Cai, Ping Lei, Yinuo Chen, Wenting Zou, Chune Dong, Ke Lan,* Shuwen Wu* and Hai-Bing Zhou*. Bioorganic Chemistry 2022, 122, 105683. (IF: 5.307)

7. Rational Design of ERα Targeting Hypoxia Turn-on Fluorescent Probes with Antiproliferative Activity for Breast Cancer. Qiuyu Meng, Baohua Xie, Xiaoyu Ma, Zhiye Hu, Fuling Zhou, Hai-Bing Zhou*, Chune Dong*. Chem. Comm. 2020, 56 (72), 10493-10496. (IF: 5.996)

8. Identification of Dibucaine Derivatives as Novel Potent Enterovirus 2C Helicase Inhibitors: In Vitro, In Vivo, and Combination Therapy Study. Qi Tang, Zhichao Xu, Mengyu Jin, Ting Shu, Yinuo Chen, Leilei Feng, Qiuhan Zhang, Ke Lan*, Shuwen Wu* and Hai-Bing Zhou*. Eur. J. Med. Chem. 2020, 202, 112310. (IF: 5.572)

9. Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor a (ERa) and lysinespecific demethylase 1 (LSD1) for treatment of breast cancer. Ming He, Wentao Ning, Zhiye Hu, Jian Huang, Chune Dong*, Hai-Bing Zhou*. Eur. J. Med. Chem. 2020, 195, 112281. (IF: 5.572)

10. Construction of Benzofuranone Library via Metal-Free, One-Pot Intermolecular Condensation and Their Application as Efficient Estrogen Receptor β Modulators. Xueke Peng, Zhiye Hu, Jing Zhang, Wentao Ning, Silong Zhang, Chune Dong, Xiaodong Shi,* and Hai-Bing Zhou*. Chem. Comm. 2019, 55 (97), 14570–14573. (IF: 5.996)

11. Novel class of 7-Oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor a degradation activity. Zhiye Hu, Yuanyuan Li, Baohua Xie, Wentao Ning, Yuan Xiao, Yuan Huang, Chenxi Zhao, Jian Huang*, Chune Dong*, Hai-Bing Zhou*. Eur. J. Med. Chem. 2019, 182, 111605. (IF: 5.572).

12. Exploring the PROTAC Degron Candidates: OBHSA with Different Side Chains as Novel Selective Estrogen Receptor Degraders (SERDs). Yuanyuan Li, Silong Zhang, Jing Zhang, Zhiye Hu, Yuan Xiao, Jian Huang, Chune Dong,* Shengtang Huang,* and Hai-Bing Zhou*. Eur. J. Med. Chem. 2019, 172, 48-61. (IF: 5.572).

13. Novel Hybrid Conjugates with Dual Suppression of Estrogenic and Inflammatory Activities Display Significantly Improved Potency against Breast Cancer. Wentao Ning, Zhiye Hu, Chu Tang, Lu Yang, Silong Zhang, Chune Dong, Jian Huang and Hai-Bing Zhou*. J. Med. Chem. 2018, 61 (18), 8155-8173. (IF: 6.253) (Highlighted by Supplementary Cover)

14. Synthesis and structure-activity relationship study of arylsulfonamides as novel potent H5N1 inhibitors. Yongshi Yu, Qi Tang, Zhichao Xu, Siliang Li, Mengyu Jin, Zixuan Zhao, Chune Dong, Shuwen Wu, Hai-BingZhou*. Eur. J. Med. Chem. 2018, 159, 206-216. (IF: 4.816).

15. A high-affinity subtype-selective fluorescent probe for estrogen receptor β imaging in living cells. Zhiye Hu, Lu Yang, Wentao Ning, Chu Tang, Qiuyu Meng, Jie Zheng, Chune Dong, and Hai-Bing Zhou*. Chem. Comm. 2018, 54 (31), 3887-3890. (IF: 6.290) (Highlighted by Hot off the Press from Natural Product Reports on 07 Jun 2018)

16. Estrogen receptor sensing in living cells by a high affinity turn-on fluorescent probe. Lu Yang, Qiuyu Meng, Zhiye Hu, Wentao Ning, Jie Zheng, Chune Dong, Hai-Bing Zhou*. Sensors and Actuators B: Chemical 2018, 272, 589–597. (IF: 5.667).

17. A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer. Jing Dong, Nan Zheng, Xue Wang, Chu Tang, Ping Yan*, Hai-Bing Zhou*, Jian Huang*. Eur. J. Pharmacol. 2018, 828, 67-79. (IF: 3.040)

18. Full Antagonism of the Estrogen Receptor without a Prototypical Ligand Side Chain. Sathish Srinivasan, Jerome C. Nwachukwu, Nelson E. Bruno, Venkatasubramanian Dharmarajan, Devrishi Goswami, Irida Kastrati, Scott Novick, Jason Nowak, Valerie Cavett, Hai-Bing Zhou, Nittaya Boonmuen, Yuechao Zhao, Jian Min, Jonna Frasor, Benita S. Katzenellenbogen, Patrick R. Griffin, John A. Katzenellenbogen, Kendall W. Nettles*. Nature Chemical Biology 2017, 13 (1), 111-118. (IF: 13.843)

19. Recent Advances in Gossypol Derivatives and Analogues: A Chemistry and Biology View. Y. Lu, J. Li, W. Wang,* H.-B. Zhou*. Future Medicinal Chemistry 2017, 9 (11), 1243-1275. (IF: 3.969)

20. Selenophenes: Introducing a New Element into the Core of Non-Steroidal Estrogen Receptor Ligands. Silong Zhang, Zhiyong Wang, Zhiye Hu, Changhao Li, Chu Tang, Kathryn E. Carlson, Junjie Luo, Chune Dong, John A. Katzenellenbogen, Jian Huang*, Hai-Bing Zhou*. ChemMedChem 2017, 12 (3), 235–249. (IF: 3.009)

21. Identification and Structure–Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors. Xin Han, Ningyuan Sun, Haoming Wu, Deyin Guo, Po Tien, Chune Dong, Shuwen Wu*, and Hai-Bing Zhou*. J. Med. Chem. 2016, 59 (5), 2139-2150. (IF: 5.589) (Highlighted by BioCentury Innovations (Formerly SciBX, Science-Business eXchange) on March 3, 2016)

22. Predictive Features of Ligand-Specific Signaling through the Estrogen Receptor. Jerome C. Nwachukwu, Sathish Srinivasan, Yangfan Zheng, Song Wang, Jian Min, Chune Dong, Zongquan Liao, Jason Nowak, Nicholas J. Wright, René Houtman, Kathryn E. Carlson, Jatinder S. Josan, Olivier Elemento, John A. Katzenellenbogen*, Hai-Bing Zhou*, Kendall W. Nettles*. Molecular Systems Biology 2016, 12, 864. (IF: 10.581)

23. Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Anti-Tumor Activity as an Inhibitor of Antiapoptotic Proteins. Yuzhi Lu, Shuangchan Wu, Yuan Yue, Si He, Jun Li, Jun Tang, Wei Wang,* and Hai-Bing Zhou*. ACS Med. Chem. Lett. 2016, 7 (12), 1185–1190. (IF: 3.746)

24. Novel Bioactive Hybrid Compounds Dual Targeting Estrogen Receptor and Histone Deacetylase for Treatment of Breast Cancer. Chu Tang, Changhao Li, Silong Zhang, Zhiye Hu, Jun Wu, Chune Dong*, Jian Huang*, and Hai-Bing Zhou*. J. Med. Chem. 2015, 58 (11), 4550-4572. (IF: 5.589)

25. Tunable Bifunctional Phosphine Squaramide Promoted Morita-Baylis-Hillman Reaction of N-alkyl Isatins with Acrylates. Ze Dong, Chao Yan, Yongzhi Gao, Chune Dong, Guofu Qiu*, Hai-Bing Zhou*. Adv. Synth. Catal. 2015, 357 (9), 2132–2142. (IF: 6.453).

26. Triaryl-substituted Schiff Bases are High-Affinity Subtype-Selective Ligands for the Estrogen Receptor. Zong-Quan Liao, Chune Dong, Kathryn E. Carlson, Sathish Srinivasan, Jerome C. Nwachukwu, Robert W. Chesnut, Abhishek Sharma, Kendall W. Nettles, John A. Katzenellenbogen,* and Hai-Bing Zhou*. J. Med. Chem. 2014, 57 (8), 3532-3545. (IF: 5.447)

27. C3-Symmetric Cinchonine-Squaramide-Catalyzed Asymmetric Chlorolactonization of Styrene-Type Carboxylic Acids with 1,3-Dichloro-5,5-dimethylhydantoin: An Efficient Method to Chiral Isochroman-1-ones. Xin Han, Chune Dong, and Hai-Bing Zhou*. Adv. Synth. Catal. 2014, 356 (6), 1275–1280. (IF: 5.663).

28. Synthesis and SARs of Indole-based α-Amino Acids as Potent HIV-1 Non-Nucleoside Reversed Transcriptase Inhibitors. Xin Han, Haoming Wu, Wei Wang, Chune Dong, Po Tien, Shuwen Wu*, Hai-Bing Zhou*. Org. Biomol. Chem. 2014, 12 (41), 8308 - 8317. (IF: 3.562)

29. Thiophene-Core Estrogen Receptor Ligands Having Superagonist Activity. Jian Min, Pengcheng Wang, Sathish Srinivasan, Jerome C. Nwachukwu, Pu Guo, Minjian Huang, Kathryn E. Carlson, John A. Katzenellenbogen*, Kendall W. Nettles, Hai-Bing Zhou*. J. Med. Chem. 2013, 56 (8), 3346–3366. (IF: 5.480)

30. Enantioselective inhibition of reverse transcriptase (RT) of HIV-1 by non-racemic indole-based trifluoropropanoates developed by asymmetric catalysis using recyclable organocatalysts. Xin Han, Wenjie Ouyang, Bin Liu, Wei Wang*, Po Tien, Shuwen Wu*, Hai-Bing Zhou*. Org. Biomol. Chem. 2013, 11 (48), 8463-8475. (IF: 3.487)

31. Identification and Structure-Activity Relationships of a Novel Series of Estrogen Receptor Ligands Based on 7-Thiabicyclo[2.2.1]hept-2-ene-7-oxide. Pengcheng Wang, Jian Min, Jerome C. Nwachukwu, Valerie Cavett, Kathryn E. Carlson, Pu Guo, Manghong Zhu, Yangfan Zheng, Chune Dong, John A. Katzenellenbogen*, Kendall W. Nettles, Hai-Bing Zhou*. J. Med. Chem. 2012, 55 (5), 2324-2341. (IF: 5.614)

32. Development of Selective Estrogen Receptor Modulator (SERM)-Like Activity Through an Indirect Mechanism of Estrogen Receptor Antagonism: Defining the Binding Mode of 7-Oxabicyclo[2.2.1]hept-5-ene Scaffold Core Ligands. Yangfan Zheng, Manghong Zhu, Sathish Srinivasan, Jerome C. Nwachukwu, Valerie Cavett, Jian Min, Kathryn E. Carlson, Pengcheng Wang, Chune Dong, John A. Katzenellenbogen*, Kendall W. Nettles, Hai-Bing Zhou*. ChemMedChem 2012, 7 (6), 1094-1100. (IF: 2.835)